PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
Puma Biotechnology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Market Cap | $527.04M | $166.30M |
| Enterprise Value | $440.24M | $88.19M |
| PE Ratio | 19.63 | 20.44 |
| PS Ratio | 2.28 | 3.65 |
| PB Ratio | 3.80 | 2.03 |
| P/TBV Ratio | 3.80 | 2.29 |
| P/FCF Ratio | 12.81 | 17.44 |
| P/OCF Ratio | 12.81 | 12.98 |
Enterprise value
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| EV / Sales | 1.90 | 2.51 |
| EV / EBITDA | 10.76 | 14.65 |
| EV / EBIT | 14.46 | 19.00 |
| EV / FCF | 10.70 | 20.86 |
Income (trailing twelve months)
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Revenue | $231.24M | $58.34M |
| Gross Profit | $173.05M | $105.94M |
| Operating Income | $30.44M | -$21.40M |
| Pretax Income | $31.17M | -$14.34M |
| Net Income | $26.72M | -$22.46M |
| EBITDA | $40.92M | -$16.91M |
| EPS (Diluted) | $0.52 | -$0.83 |
Margins
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Gross Margin | 74.8% | 52.9% |
| Operating Margin | 13.2% | -44.0% |
| Pretax Margin | 13.5% | -13.3% |
| Profit Margin | 11.6% | -40.2% |
| EBITDA Margin | 17.7% | -30.2% |
| FCF Margin | 17.8% | -9.27% |
Returns
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Return on Equity (ROE) | 22.0% | -53.2% |
| Return on Assets (ROA) | 13.8% | -40.9% |
| Return on Invested Capital (ROIC) | 42.7% | -32.4% |
| Return on Capital Employed (ROCE) | 21.3% | -38.1% |
Growth
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -2.86% | 5.96% |
| Net Income Growth (YoY) | -44.9% | -35.2% |
| EPS Growth (YoY) | -46.9% | -26.2% |
| FCF Growth (YoY) | -6.93% | 2.34% |
| Revenue Growth (3Y CAGR) | 0.05% | 2.25% |
| Revenue Growth (5Y CAGR) | 0.29% | 6.48% |
Balance sheet
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $86.80M | $61.43M |
| Total Debt | $0 | $118.52M |
| Net Cash (Debt) | $86.80M | $15.35M |
| Net Cash Per Share | $1.68 | $0.66 |
| Equity (Book Value) | $138.54M | $49.09M |
| Book Value Per Share | $2.68 | $1.37 |
| Tangible Book Value | $138.54M | $23.52M |
| Working Capital | $95.25M | $76.81M |
Financial position
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Current Ratio | 2.91 | 3.34 |
| Quick Ratio | 2.43 | 2.44 |
| Debt / Equity | 0.00 | 0.52 |
| Debt / EBITDA | 0.00 | 3.44 |
| Debt / FCF | 0.00 | 4.89 |
| Net Debt / EBITDA | -2.12 | 2.36 |
| Interest Coverage | 8.65 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Operating Cash Flow | $41.15M | -$12.35M |
| Capital Expenditures | $10.00K | -$1.08M |
| Free Cash Flow | $41.16M | -$20.22M |
| FCF Per Share | $0.80 | -$0.42 |
Efficiency
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Asset Turnover | 1.19 | 0.39 |
| Inventory Turnover | 5.31 | 2.70 |
| Revenue Per Employee | $1.29M | $404.87K |
| Profits Per Employee | $149.26K | -$703.34K |
| Employee Count | 179 | 74 |
Dividends and yields
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Earnings Yield | 5.07% | -23.3% |
| FCF Yield | 7.81% | -8.72% |
Shares
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Shares Outstanding | 51,620,100 | 58,127,000 |
| Shares Change (YoY) | 3.74% | 10.9% |
| Shares Change (QoQ) | 0.44% | 0.54% |
| Float | 41,841,700 | 49,136,700 |
| Shares Held by Insiders | 18.9% | 11.6% |
| Shares Held by Institutions | 74.9% | 59.4% |
Scores
| Measure | Puma Biotechnology | Industry median |
|---|---|---|
| Graham Number | $5.60 | $18.73 |
| Graham Upside | -45.1% | -45.1% |
| Altman Z-Score | -1.14 | -0.22 |
| Piotroski F-Score | 8 | 4 |
| Beneish M-Score | -2.06 | -2.62 |
Calculated by StockData from Puma Biotechnology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.